Funded by: 2020 MSH Research Support Scheme – 2020 Program Grants
Research from our group has found that people with schizophrenia are 3 times more likely to die earlier than the general population, leading to a gap in life expectancy of over 16 years. The main causes for this mortality gap are avertable cardiometabolic diseases, notably cardiovascular disease, diabetes, obesity and metabolic syndrome. People with schizophrenia have a genetic predisposition to abnormal blood glucose, but also have
poor diet, high levels of sedentary behaviour, and are subject to the obesogenic effects of antipsychotic medications. One in three people with schizophrenia do not respond to first or second line antipsychotics. For these people with treatment refractory schizophrenia, clozapine is by far the most effective antipsychotic. However, clozapine is associated with the highest rates of metabolic disturbance and obesity.
Our research aims to tackle the modifiable causes of cardiometabolic disease with a goal of reducing the mortality gap for people with schizophrenia. The program grant takes a biopsycho-social approach via pharmacological and lifestyle (diet and exercise) interventions for metabolic disorders. Our MExiCO trial builds on our pilot studies to run a definitive RCT of exenatide for people with clozapine associated obesity not responsive to metformin. The RIPENS study is an implementation study of evidence-based lifestyle interventions within a large public mental health service at Metro South. This multi-faceted approach to addressing the burden of disease is innovative, and highly grounded in the clinical service in which we operate, increasing the clinical translation capacity of this program.
Do you want to know more about QCMHR, but can’t quite get enough information from our website? Please get in touch – we are happy to help!
Level 3, Dawson House
The Park Centre for Mental Health Treatment,
Research and Education, Wacol,
P: +61 7 3271 8704
F: +61 7 3271 8698
Copyright 2021 QCMHR | Site map | Privacy | Terms and Conditions | Web development by iFactory